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Background: Oxaliplatin is used as a neo-adjuvant therapy in hepatic colorectal carcinoma metastasis. This treatment has significant
side effects, as oxaliplatin is toxic to the sinusoidal endothelial cells and can induce sinusoidal obstruction syndrome (SOS), which is
related to decreased overall survival. Glutathione has an important role in the defence system, catalysed by glutathione S-transferase
(GST), including two non-enzyme producing polymorphisms (GSTM1-null and GSTT1-null). We hypothesise that patients with a non-
enzyme producing polymorphism have a higher risk of developing toxic injury owing to oxaliplatin.
Methods: In the nontumour-bearing liver, the presence of SOS was studied histopathologically. The genotype was determined
by a semi-nested PCR.
Results: Thirty-two of the 55 (58%) patients showed SOS lesions, consisting of 27% mild, 22% moderate and 9% severe lesions.
The GSTM1-null genotype was present in 25 of the 55 (46%). Multivariate analysis showed that the GSTM1-null genotype
significantly correlated with the presence of (moderate–severe) SOS (P¼ 0.026).
Conclusion: The GSTM1-null genotype is an independent risk factor for SOS. This finding allows us, in association with other risk
factors, to conceive a potential risk profile predicting whether the patient is at risk of developing SOS, before starting oxaliplatin,
and subsequently might result in adjustment of treatment.
Colorectal cancer is responsible for 1.2 million new cancer cases
and 608 700 deaths in 2008 worldwide (Jemal et al, 2011).
Fatal outcome as a rule is the result of metastatic disease. The
liver is the most common site of metastases and at time of
diagnosis 15–20% of the patients have already developed liver
metastases (Adam, 2007). If the liver metastases can be removed
completely by surgery, a 5-year survival ofB50% can be achieved
(Choti et al, 2002; Fernandez et al, 2004). Most patients are not
eligible for surgery, owing to the high number of liver metastases,
their size and/or their location. Currently, these initially inoperable
patients receive neo-adjuvant chemotherapy, for example, oxali-
platin and bevacizumab (Alberts et al, 2005; Jatoi et al, 2006),
which might make the liver metastases operable and the patient
potentially curable; this can be achieved in 15% of the patients with
a 5-year survival of 33% (Adam et al, 2004; Rubbia-Brandt et al,
2007).
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This approach, however, is associated with significant side
effects. Up to 74% of the patients develop sinusoidal obstruction
syndrome (SOS) (Rubbia-Brandt et al, 2004, 2010; Ward et al,
2008) in the nontumour-bearing liver, causing a higher incidence
of postoperative complications and decreased overall survival
(Nakano et al, 2008; Rubbia-Brandt, 2010; Tamandl et al, 2011).
Sinusoidal obstruction syndrome is initiated by toxic injury to
sinusoidal endothelial cells (SECs), which can cause different
degrees of vascular damage, namely sinusoidal obstruction,
perisinusoidal fibrosis, centrilobular hepatic vein fibrotic obstruc-
tion, nodular regenerative hyperplasia (NRH) and peliosis
(Rubbia-Brandt, 2010).
The cytotoxicity of oxaliplatin, a platinum drug, is caused by
intrastrand crosslinks between platinum and DNA, eventually
leading to tumour cell apoptosis (Rabik and Dolan, 2007). Cellular
defence is possible by DNA repair mechanisms and inactivation of
the platinum compound by glutathione and other anti-oxidants
(Wang et al, 2000; Kweekel et al, 2005; Rabik and Dolan, 2007;
Furuta, 2009). Glutathione forms an adduct with platinum,
subsequently leading to detoxification of oxaliplatin. This adduct
formation is catalysed by glutathione S-transferase enzyme (GST)
(Kweekel et al, 2005). Several subclasses of GST are known, in
which y (GSTT), m (GSTM), a (GSTA), p (GSTP) and o (GSTO)
are best characterised, each with their own polymorphism (Di
Pietro et al, 2010). In contrast to the other known polymorphisms,
both GSTT and GSTM have a null genotype, respectively, GSTT1-
null and GSTM1-null. The null genotypes concern a complete gene
deletion, resulting in no functional enzymatic activity. Lack of
enzymatic GST function leads to a decreased adduct formation
between glutathione and platinum and, consequently, a decreased
defence mechanism against oxaliplatin (Kweekel et al, 2005;
Furuta, 2009).
Not every patient develops SOS (Rubbia-Brandt et al, 2004,
2010; Ward et al, 2008); this individual vulnerability might result
from deficiencies in the detoxification process. As GST is a part of
the cellular defence mechanism, we hypothesised that patients with
a GSTT1-null and/or GSTM1-null genotype have a higher risk of
developing the toxic injury owing to oxaliplatin, namely SOS.
Among the studied risk factors (Nakano et al, 2008), a genetic
factor has not been reported so far. Identification of such a risk
factor might be clinically important, as therapies aiming at the
prevention of SOS are currently under study (Lehmann et al,
2012). The aim of this study was to research the impact of the
GSTM1-null and/or GSTT1-null genotypes on the risk of
developing SOS, in oxaliplatin-treated patients with colorectal
liver metastases.
MATERIALS AND METHODS
Patients. Included were all patients with colorectal liver metas-
tases, who initially underwent a partial hepatic resection at the
Maastricht University Medical Centre between January 2008 and
December 2009. Exclusion criteria were: no neo-adjuvant treat-
ment or neo-adjuvant treatment not containing oxaliplatin or
non-adequate histopathological material (e.g., no presence of
nontumour-bearing liver on a distance of more than 2 cm from the
tumour). The basic treatment schedule was 6 cycles of oxaliplatin
(130mg/m2 once in 3 weeks). The actual number of treatment
cycles differed per patient, depending on the radiological response
according to Response Criteria In Solid Tumours (Husband et al,
2004), in combination with the patient’s physical condition and
the sustained side effects (e.g., neurotoxicity). The study was
performed in accordance with the ethical standards of the
Declaration of Helsinki, and written informed consent was
obtained from each patient.
Methods. The hepatectomy specimens were sliced before fixation.
After fixation (4% buffered formaldehyde), several tissue samples
were taken from the nontumour-bearing liver (at a minimum
distance of 2 cm from the lesion), avoiding the subcapsular region.
The tissue samples were routinely embedded in paraffin and 4 mm
sections were cut.
Sinusoidal obstruction syndrome. Morphological analysis was
based on haematoxylin and eosin, reticulin and Trichrome
Masson stains. Histopathological features containing vascular and
parenchymal changes were graded categorically, according to the
scheme of Rubbia-Brandt et al (2010).
Based on these criteria, sinusoidal dilatation was graded as
follows: 0, absent; 1, mild (centrilobular involvement limited to
one-third of the lobular area); 2, moderate (centrilobular involve-
ment extending in two-thirds of the lobular area) and 3, severe
(complete lobular involvement or centrilobular involvement
extending to adjacent lobules with bridging congestion). All
histological sections were examined by two experienced hepato-
biliary pathologists (AD–AW), unaware of the clinical data and the
GSTM1 and GSTT1 polymorphism; in case of discrepancy, the
section was discussed at the dual head microscope and consensus
was reached.
GSTM1 and GSTT1 polymorphism analysis. The genomic
DNA was extracted from formalin-fixed, paraffin-embedded
nontumour-bearing liver tissue samples, with the Puregene DNA
Isolation Kit (Gentra Systems, Minneapolis, MN, USA). The
manufacter’s protocol was followed, using 10 thick (10 mm)
macrodissected sections. The DNA purity was controlled by the
NanoDrop ND-1000 Spectrophotometer (Isogen Life Sciences, De
Meern, The Netherlands). Products with an A260/A280 ratio
between 1.8 and 2.0 were regarded as pure and protein-free DNA.
A semi-nested multiplex PCR was used for simultaneous
assessment of the GSTM1 and GSTT1 genes, using b-globine as
an internal control. The semi-nested technique was indicated
owing to the DNA extraction from paraffin-embedded tissue and
the length of the fragments (219–290 base pairs), as a semi-nested
PCR is more successful in specifically amplifying long DNA
products compared with conventional PCR.
The first PCR product (1 : 100 dilution) served as a template for
the second PCR. In each PCR, one round of 35 cycles was
performed. The primer sequences, of both first and second PCR,
are listed in Table 1. Subsequently, electrophoretic analysis was
performed, visualising the amplified product by gelstar in a 2%
agarose gel.
As one of the primers is located in the deleted sequence, this
technique enabled us to identify the homozygous null genotype.
However, differentiation between the deletional heterozygotes and
the nondeletional homozygotes is not possible, both of which we
defined as GSTM1-positive or GSTT1-positive genotype.
Statistics. For statistical analysis, we combined the absence of SOS
lesions (grade 0) and mild lesions (grade 1), and also the moderate
(grade 2) and severe (grade 3) SOS lesions, resulting into two
groups (absent–mild lesions and moderate–severe lesions). A
multivariate logistic regression analysis was used to correlate the
GSTM1-null genotype, GSTT1-null genotype, GSTM1-null/
GSTT1-null genotype and cumulative amount of oxaliplatin, in
the presence of SOS (0¼ absent–mild and 1¼moderate–severe).
As applicable, a w2 test or Student t-test was used for analysis of
baseline features of the different groups, concerning GSTM1-null
and GSTM1-pos. All statistical analyses were performed using
SPSS 15.0 statistical software (SPSS, Chicago, IL, USA). For all
tests, Po0.05 was considered to indicate statistical significance.
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RESULTS
Patients. Between January 2008 and December 2009, 80 Cauca-
sian patients underwent a first partial hepatectomy for colorectal
liver metastases at the Maastricht University Medical Centre. After
excluding patients for no neo-adjuvant treatment or neo-adjuvant
treatment not containing oxaliplatin (n¼ 22) and lack of adequate
histopathological material (n¼ 3), 55 patients were available for
analysis. There were 28 males and 27 females, mean age 62 years
(range 40–81). All patients received oxaliplatin with a median
number of six cycles (range 1–12), leading to a mean cumulative
dose of OX 650mgm 2 (range 130–1560), all over treatment.
Thirty-eight patients received additional bevacizumab.
SOS, GSTM1 and GSTT1 genotype. Thirty-two of the 55 (58%)
patients showed SOS lesions, resulting in 69% absent–mild and
31% moderate–severe. The cumulative dose of oxaliplatin showed a
significant difference between the absent–mild and moderate–
severe group (649mgm 2 vs 818mgm 2; P¼ 0.040).
The DNA purity, measured in A260/A280, had a mean value of
1.92 (range 1.89–1.99), concluding that the samples were pure and
protein-free. Twenty-five of the 55 (46%) patients had the GSTM1-null
genotype. The GSTM1-null genotype showed a significantly higher
incidence of moderate–severe SOS, compared with the GSTM1-
positive genotype (48% vs 17%, P¼ 0.013), (Table 2). The GSTT1-null
genotype was present in 9 of the 55 (17%) patients. Only four (7%)
patients had a combined GSTM1-null/GSTT1-null genotype.
Multivariate analysis showed that the GSTM1-null genotype
correlated significantly with the presence of moderate–severe
SOS (P¼ 0.026). The GSTT1-null genotype and the combined
GSTM1-null/GSTT-null genotype showed no significant correla-
tion (P40.05). Furthermore, the cumulative amount of oxaliplatin
was positively correlated with the presence of moderate–severe
SOS (P¼ 0.105) (Table 3).
DISCUSSION
Sinusoidal obstruction syndrome is a frequent complication of
oxaliplatin treatment. The clinical consequences may vary between
longer hospitalisation and decreased overall survival (Nakano et al,
2008; Rubbia-Brandt, 2010; Tamandl et al, 2011). The present trial
was designed to identify the presence of genetic variance in the
glutathione allele as risk factor for SOS. We provide novel data that
the GSTM1-null genotype is significantly positively related with
the presence of moderate–severe SOS, making it an independent
risk factor for the development of SOS.
In the nontumour-bearing liver, SOS covers a spectrum of
pathological features consisting of sinusoidal obstruction, perisinu-
soidal fibrosis, centrolobular hepatic vein fibrotic obstruction, NRH
and peliosis (Rubbia-Brandt, 2010). The initial damage occurs in the
SECs, leading to detachment of the SECs and obstruction of the
sinusoid (DeLeve et al, 1999). Better understanding of this initial
damage and the SEC defence system is needed and might lead to new
insights in the onset and, subsequently, the treatment of SOS.
The incidence of the GSTM1-null and the GSTT1-null genotype
in our population was 46% and 17%, respectively, which is
comparable with the published literature for Caucasians (50% and
20%, respectively) (Dong et al, 2008). Our study showed that the
GSTM1-null genotype was positively related with the presence of
moderate–severe SOS, making it an independent risk factor for the
development of SOS. This finding is consistent with the
pathophysiology; the GSTM1-null genotype does not lead to an
enzyme production, subsequently the binding of reactive platinum
compounds to glutathione is not catalysed and the excessive
damage to the SECs manifests itself in SOS. In addition, the
GSTT1-null genotype seems to be less important in this process, as
there was no correlation between the GSTT1-null genotype, nor
the GSTM1-null/ GSTT1-null genotype, and SOS.
To our best knowledge, only one previous study by
Srivastava et al (2004) has investigated the correlation between
the GSTM1-null genotype and SOS, yet in another setting. In this
study, bone marrow transplant patients were treated with busulfan
and cyclophosphamide. Sinusoidal obstruction syndrome was
diagnosed clinically, using the Baltimore criteria (Jones et al,
1987). They showed a significant positive correlation between the
GSTM1-null genotype and SOS. Our study differs in treatment and
diagnostic test, as we have diagnosed SOS histologically. Given the
fact that both studies prove the importance of the GSTM1-null
genotype supports the theory that glutathione has a key role in the
pathogenesis of SOS. Deleve (1994) were the first to demonstrate
this and to suggest that all SOS-inducing agents are more harmful
for SECs than for hepatocytes, based on the lower glutathione
levels in SECs (Wang et al, 2000). In addition, they showed that
continuous glutathione infusion protects against SOS in an
experimental rat model (Wang et al, 2000).
Although it is thought that glutathione has an important
protective role in the initial damage, we noticed in our study that a
few patients, which had the GSTM1-positive genotype, developed
SOS. Several explanations for this finding should be considered.
First, this finding might assume that the cumulative amount of
oxaliplatin eventually determines whether a patient develops SOS.
This leads us to the theory that every patient in the end develops
SOS, if a sufficient dose of oxaliplatin is given. The cumulative
amount, at which the patient develops SOS, depends on the
patients vulnerability. Our data support this theory by a positive
correlation between the cumulative dose of oxaliplatin and the
presence of moderate–severe SOS (P¼ 0.105) (Table 3). Second,
the initial toxic SEC damage is a multifactorial process, where in
the human defence system glutathione has a role only partially.
This defence system consists of DNA repair mechanisms and anti-
oxidants (Wang et al, 2000; Kweekel et al, 2005; Rabik and Dolan,
Table 1. Primer sequences of GSTM1 and GSTT1 genotype
Primer designation Sequences
Product
length
(bp)
GSTM1
First amplification
Forward 50-GAACTCCCTGAAAAGCTAAAGC-30 219
Reverse 50-GTTGGGCTCAAATATACGGTGG-30
Second amplification
Forward 50-CAGAGTTTCTGGGGAAGCGG-30 191
Reverse idem first amplification
GSTT1
First amplification
Forward 50-TTCCTTACTGGTCCTCACATCTC-30 290
Reverse 50-AAGACTTGGCAGCCAGCACC-30
Second amplification
Forward idem first amplification 249
Reverse 50-TACAGACTGGGGATGGATGG-30
b-globine
First amplification
Forward 50-GAAGAGCCAAGGACAGGTAC-30 268
Reverse 50-CAACTTCATCCACGTTCACC-30
Second amplification
Forward 50-GGCTGGGCATAAAAGTCAGG-30 162
Reverse idem first amplification
Abbreviations: bp¼base pairs; GSTM¼glutathione S-transferase enzyme m; GSTT¼
glutathione S-transferase enzyme y.
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2007; Furuta, 2009), where the precise role of both, with regards to
oxaliplatin, is not entirely clear. Improvement of the knowledge on
the process of damage and the protection mechanisms involved
might lead to the discovery of new treatment options of SOS and
possibly also to preventive measures to avoid this injury.
A recent article by Rubbia-Brandt et al emphasises even more
the genetic importance in the initial damage of SOS, as they
described genes which are up- or downregulated in the presence of
SOS, leading to a molecular signature. The oxidative stress pathway
showed a major gene upregulation, which is meaningful in the
initial SEC damage and cellular defence system (Rubbia-Brandt
et al, 2011).
Our study harbours a limitation, as 69% of the patients have
received additional bevacizumab, which has been shown to work
protective against SOS (Rubbia-Brandt et al, 2010). Additional
bevacizumab is recommended in the guidelines (Kabbinavar et al,
2005). As these patients are equally divided among both groups
(GSTM1-null and GSTM1-pos), it is less likely that this drug
would influence our results. However, a more ideal comparison
would consist of patients solely treated with oxaliplatin.
In conclusion, the present study showed that the GSTM1-null
genotype is significantly positively correlated with the presence of
moderate–severe SOS, making it an independent risk factor for the
development of SOS in oxaliplatin treatment. Our finding could
contribute to a genetic risk profile, predicting whether the patient
is at risk for developing SOS, before starting treatment, and may
subsequently result in adjustment of the cumulative amount of
oxaliplatin, but further prospective research is needed to evaluate this.
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